ArticleInternational journal of nanomedicine2025
Polydopamine Dual-Modal Nanotherapy Synergizes Photothermal Antibacterial and Nanozyme Anti-Inflammatory Effects for Periodontitis Treatment.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-Enzyme Mimetic Molybdenum Nitride Nanozymes Reshape Subgingival Microenvironment for Synergistic Periodontitis Therapy via ROS Regulation and Microbiome Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanoscale Approaches to Oro-Dental Tissue Engineering: A Review of Strategies, Composites, and Translational Challenges.International journal of nanomedicine · 2026Review
- Pre-chelated gallium-loaded polydopamine nanoparticles as a multifunctional regulator of osteoblast/osteoclastogenesis for the synergistic therapy of periodontitis.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Given the limitations associated with clinical curettage in the treatment of periodontitis, there is a pressing need to enhance the complete removal of plaque from deep periodontal pockets and to facilitate the repair of periodontal tissues through appropriate medical interventions. Despite the significant advancements of various local drug delivery systems (LDDS) for the adjunctive treatment of periodontitis, their efficacy remains constrained by two intertwined challenges: inadequate antibiofilm capability and excessive reactive oxygen species (ROS)-mediated tissue damage. Methods: To simultaneously overcome these dual barriers, we synthesized polydopamine nanoparticles (PDA NPs) through a straightforward and efficient self-polymerization process of dopamine, followed by the synthesis of nanoparticles on the surface via reductive methods to create multifunctional nanoplatforms (PAg). Results: Notably, these PDA nanoparticles, which are based on comprehensive nanocomposites, function as photothermal agents that enhance the therapeutic efficacy against biofilms in vitro through antibacterial photothermal therapy (PTT) under near-infrared laser irradiation. Furthermore, owing to the enzyme-like activity of PDA nanozyme, the engineered nanocomposite is capable of effectively scavenging ROS in Raw267.4 cells and human periodontal ligament cells under oxidative stress conditions. The in vitro and in vivo analyses demonstrated that live/dead staining of the biofilm, along with Western blot assessments of inflammatory markers, substantially augmented the antibacterial and anti-inflammatory efficacy. The nano-platform-based PAg nanoparticles developed in our study not only markedly enhanced the antibacterial effect through combination therapy but also efficiently reduced cellular ROS via the enzyme-like activity of the nanozyme. Conclusion: This dual-modal nanotherapy delivers a coordinated attack on periodontitis pathogenesis, including direct physical elimination of biofilms coupled with ROS scavenging to mitigate collateral tissue damage, thereby addressing the limitations of current LDDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.